Position in GANX
as of Jun 30, 2026
· filed Aug 6, 2026
Position Value
$1,283,225
+$677,040 QoQ
Shares Held
632,131
+102.3% QoQ
Ownership
1.45%
of shares outstanding
% of Portfolio
0.09%
of 13F equity value
Holder Rank
#3
of 49 holders
Holding Since
Jun 2025
4 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in GANX Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026GSA CAPITAL PARTNERS LLP holds $104,909,103 across 164 Biotechnology names. GANX ranks #24 (1.2% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | IOVA |
Iovance Biotherapeutics, Inc.
|
655,318 | $2,726,122 | |
| 2 | IMVT |
Immunovant, Inc.
|
65,267 | $2,514,737 | |
| 3 | GOSS |
Gossamer Bio, Inc.
|
14,986,947 | $2,472,846 | |
| 4 | AXSM |
Axsome Therapeutics, Inc.
|
9,419 | $2,305,488 | |
| 5 | CABA |
Cabaletta Bio, Inc.
|
668,563 | $2,079,230 | |
| 6 | MLTX |
MoonLake Immunotherapeutics
|
106,695 | $2,077,351 | |
| 7 | ATYR |
aTYR PHARMA INC
|
3,454,863 | $2,062,553 | |
| 8 | CORT |
Corcept Therapeutics Inc
|
23,257 | $2,022,196 |
All Filings in GANX
Export CSV
4 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $1,283,225 | 632,131 | Shares | Sole | 2026-08-06 | |
| 2026-03-31 | $606,185 | 312,467 | Shares | Sole | 2026-05-08 | |
| 2025-12-31 | $65,919 | 20,472 | Shares | Sole | 2026-02-06 | |
| 2025-06-30 | $22,960 | 12,756 | Shares | Sole | 2025-07-22 | |
| No filing history on record for this holder in this stock. | ||||||